Anti-inflammatory effects of nobiletin on TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in prostate cancer cells

Asuman Deveci Ozkan1, Suleyman Kaleli1, Hacer Ilke Onen2

  • 1Department of Medical Biology, Faculty of Medicine, Sakarya University, Sakarya, Turkey.

Insights

Nobiletin (NOB) suppresses Toll-like receptor (TLR) 4 and TLR9 signaling pathways in prostate cancer (PCa) cells. This flavonoid demonstrates anti-inflammatory effects, offering potential therapeutic strategies for PCa treatment.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Toll-like receptors (TLRs) are implicated in both cancer promotion and suppression, with TLR4 and TLR9 having significant roles in prostate cancer (PCa) progression.
  • Nobiletin (NOB), a flavonoid, exhibits anti-cancer properties in PCa cells, but its anti-inflammatory effects on TLR signaling remain uninvestigated.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of NOB on TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in PCa cell lines.
  • To explore NOB's potential as a therapeutic agent targeting TLR-mediated inflammation in prostate cancer.

Main Methods:

  • Cytotoxic effects of NOB were assessed using WST-1 assay in PC-3 and LNCaP PCa cell lines.
  • Inhibitory effects on TLR4/TRIF/IRF3 and TLR9/IRF7 pathways were evaluated via RT-PCR, western blotting, and ELISA.

Main Results:

  • NOB inhibited PCa cell growth, with LNCaP cells showing higher sensitivity due to androgen receptor status.
  • NOB suppressed TLR4/TRIF/IRF3 and TLR9/IRF7 pathways by downregulating mRNA and protein levels and reducing IFN-α and IFN-β release.

Conclusions:

  • NOB demonstrates potential to inhibit TLR4 and TLR9 signaling pathways in PCa cells.
  • The efficacy of NOB varies based on PCa cell hormone status and aggressiveness, suggesting a targeted therapeutic approach.